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Background: The molecular mechanisms underlying autistic behaviors remain to be elucidated. Mutations in genes
linked to autism adversely affect molecules regulating dendritic spine formation, function and plasticity, and some
increase the mammalian target of rapamycin, mTOR, a regulator of protein synthesis at spines. Here, we
investigated whether the Akt/mTOR pathway is disrupted in idiopathic autism and in rats exposed to valproic acid,
an animal model exhibiting autistic-like behavior.
Methods: Components of the mTOR pathway were assayed by Western blotting in postmortem fusiform gyrus
samples from 11 subjects with idiopathic autism and 13 controls and in valproic acid versus saline-exposed rat
neocortex. Additionally, protein levels of brain-derived neurotrophic factor receptor (TrkB) isoforms and the
postsynaptic organizing molecule PSD-95 were measured in autistic versus control subjects.
Results: Full-length TrkB, PI3K, Akt, phosphorylated and total mTOR, p70S6 kinase, eIF4B and PSD-95 were reduced in
autistic versus control fusiform gyrus. Similarly, phosphorylated and total Akt, mTOR and 4E-BP1 and phosphorylated S6
protein were decreased in valproic acid- versus saline-exposed rats. However, no changes in 4E-BP1 or eIF4E were
found in autistic brains.
Conclusions: In contrast to some monogenic disorders with high rates of autism, our data demonstrate
down-regulation of the Akt/mTOR pathway, specifically via p70S6K/eIF4B, in idiopathic autism. These findings suggest
that disruption of this pathway in either direction is widespread in autism and can have adverse consequences for
synaptic function. The use of valproic acid, a histone deacetylase inhibitor, in rats successfully modeled these changes,
implicating an epigenetic mechanism in these pathway disruptions.
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Autism is a neurodevelopmental disorder characterized by
social communication and interaction impairments and
restricted, repetitive patterns of behavior [1]. While it is
believed that defects in the establishment and mainten-
ance of functional neuronal networks due to synaptic/
spine dysfunction underlie the clinical symptomatology of
autism, the molecular mechanisms causing these defects
remain unknown. Several studies point to the Akt/mTOR
pathway, which regulates translation at dendritic spines* Correspondence: fahnest@mcmaster.ca
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unless otherwise stated.[2,3], as a potential molecular substrate of autism. Indeed,
mutations in genes encoding Akt-mTOR cascade compo-
nents cause disorders with high rates of autism [2-5]. Add-
itionally, autism-like phenotypes have been observed in
Eif4ebp2 knockout and eIF4E-overexpressing mice [6],
both downstream mTOR effectors regulating protein
translation. These findings strengthen the hypothesis that
disruptions in the mTOR pathway contribute to autism
neuropathology, likely by negatively affecting spines,
which are perturbed in subjects with autism [7]. Nonethe-
less, protein products of these genes have not been exam-
ined in idiopathic autism.
Valproic acid (VPA) is widely used as an antiepileptic
drug [8] and for the treatment of mood disorders [9,10].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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closure causes autism-like symptoms in humans [11-13].
Clinical effects of maternal challenge with VPA, includ-
ing impaired social interactions, stereotypical hyperactiv-
ity and sensory/communication deficits have been
reproduced in both rats and mice [14-17]. In particular,
prenatally VPA-exposed rats exhibit not only autistic-
like behaviors [18,19] but also anatomical and molecular
alterations similar to human autism including reductions
in cerebellar volume and numbers of Purkinje cells
[20,21], altered monoamine levels [22], decreased ex-
pression of the autism-linked gene, neuroligin 3 [23],
and perturbed cortical connectivity along with abnormal
synapse formation and pruning [24,25]. VPA’s ability to
inhibit histone deacetylase (HDAC) has been associated
with autistic-like behavioural, anatomical and biochem-
ical deficits in mice prenatally exposed to this drug [17],
supporting the hypothesis that epigenetic mechanisms
contribute to autism etiology. Indeed, mounting evi-
dence highlights the involvement of epigenetic factors in
synaptic dysfunction and disrupted cortical circuitry
causing autistic traits [26,27]. However, the affected sig-
nal transduction pathways remain to be identified.
In the present study, we investigated whether the Akt/
mTOR pathway, which is disrupted in monogenic disor-
ders with high rates of autism, is altered in idiopathic
autism. We specifically examined idiopathic autism, that
is, subjects without known genetic causes of autism and
without related disorders on the spectrum. We also ex-
amined whether VPA exposure in rats affects this path-
way. We measured protein levels of mTOR and its
upstream/downstream effectors in brains from subjects
with idiopathic autism versus control subjects and in
VPA- versus saline-exposed rats. Contrary to disruptions
seen in Fragile X syndrome, tuberous sclerosis, PTEN-
related macrocephaly and neurofibromatosis type 1, de-
velopmental disorders with high rates of autism, we
demonstrated decreased Akt/mTOR pathway in both
patients with idiopathic autism and in VPA-exposed rats.
These findings support the hypothesis that alterations in
Akt/mTOR signaling in either direction contribute to
autistic behavior, likely by affecting dendritic spines.
Additionally, similar molecular changes in VPA-exposed
rats suggest that epigenetic changes may underlie the
synaptic deficits characteristic of idiopathic autism.
Materials and methods
Human brain tissue samples
All experimental protocols were approved by the
Research Ethics Board of McMaster University. Frozen
samples consisting of eleven post-mortem fusiform gyrus
samples from subjects with idiopathic autism (3 females,
8 males) and thirteen control brain samples (3 females,
10 males) were provided to us by the Autism Speaks’Autism Tissue Program (Princeton, NJ) via the Harvard
Brain Tissue Resource Centre (Belmont, MA) and the
National Institute of Child Health and Human Develop-
ment (NICHD) Brain and Tissue Bank (University of
Maryland, Baltimore, MD) and were stored at −80°C be-
fore use. Clinical information about each tissue sample
was obtained through the Autism Tissue Program online
portal [http://www.autismbrainnet.com/about-us/portal/]
[28] (Tables 1 and 2). Samples were matched as much as
possible for age, gender and post-mortem interval (PMI).
There were no significant differences between groups for
these variables [28]. Cause of death, however, differed
between samples. It was not possible to match the cause
of death due to the scarcity of available tissue. All of the
tissues were from fusiform gyrus because this area is
implicated in autism [29-32]. The diagnosis of autism
was confirmed using the Autism Diagnostic Interview-
Revised [33] post-mortem through interviews with the
parents and/or caregivers. Samples from subjects with
known genetic causes of autism spectrum and related
disorders (Rett, Asperger etc.) were excluded. Subject
characteristics are shown in Tables 1 and 2.
Animal brain tissue samples
All experimental protocols were in compliance with
the University of Calgary Conjoint Faculties Research
Ethics Approval Board. Pregnant Wistar Han rats (The
Jackson Laboratory, Bar Harbor, ME, USA or Charles
River Laboratories, Wilmington, MA, USA) were or-
dered on embryonic day 3 (E3). The sodium salt of val-
proic acid (Sigma, St. Louis, MO, USA) was dissolved
in 0.9% saline to achieve a concentration of 250 mg/ml.
The dosing volume was 500 mg/kg. On E12.5, treated
dams received a single intraperitoneal (i.p.) injection of
500 mg/kg VPA sodium salt, while control dams were
injected with only saline [17,34]. Rats were born and
reared in a quiet, temperature-controlled room and
entrained to a 12-h light–dark cycle. Male pups from
each group were sacrificed between P35-38. As the fu-
siform gyrus, which is part of the temporal and occipi-
tal lobes in humans, is not present in rodents, the
lateral temporal neocortex was collected for analysis.RNA isolation and RT-PCR
Seven autism and eleven control samples from fusi-
form gyrus were used for qRT-PCR. RNA was isolated
as described in reference [28]. Yield and purity of total
cellular RNA were determined by absorbance at 260
and 280 nm, and RNA integrity was verified by agarose
gel electrophoresis. cDNA was generated as previously
described [28]. Samples containing double-distilled
water in place of reverse transcriptase were included as
negative controls (no-RT).
Table 1 Characteristics of autism tissue samples
Sample ID# CASE # Age (years) Gender PMI (hours) Primary cause of death ADI-R Drug treatment history
A1 AN01093 56 Male 19.48 Anoxic Encephalopathy 48 N/A
A2 UMB1174 7 Female 14 Seizure, Hypotension 44 Depakote, Dilantin, Tegretol
A3 AN00764 20 Male 23.7 Auto Trauma 50 Minocin
A4 AN08792 30 Male 20.3 GastroIntestinal Bleeding 41 Phenobarbital, Mysoline, Dilantin, Depakote,
Cisapride, Clorazepate, Prolosec, Propulsid,
Reglan, Tranxene
A5 AN06420 39 Male 13.95 Cardiac Tamponade 41 Synthroid, Depakote, Risperidol, Paxil,
Blood pressure medication
A6 AN00493 27 Male 8.3 Drowning - Synthroid
A7 AN08873 5 Male 25.5 Asphyxia Due To Drowning 47 Prozac
A8 UMB797 9 Male 13 Drowning 50 Desipramine
A9 UMB1182 9 Female 24 Smoke Inhalation - N/A
A10 AN16641 9 Male 27 Seizure Disorder 46 Clonidine, Depakote, Dilantin,
Lamictal, Ritalin, Tegretol
A11 AN16115 11 Female 12.88 Seizure & Drowning in Tub 44 Adderall, Dexadrine, Dilantin, Klonopin,
Lamictal, Tegretol, Topomax
Mean 20.1 18.3
SEM (+/−) 4.9 1.8
N/A = Information Not Available; PMI = Post Mortem Interval; ADI-R = Autism Diagnostic Interview-Revised.
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ward primer, 5′-GGC CCA GAT GCT GTC ATT AT-3′,
and reverse primer, 5′-TTC TGC TCA GGA CAG AGG
TT-3′, were used to detect full length TrkB (TrkB-FL),
while truncated TrkB (TrkB-T1) was detected using for-
ward primer, 5′-TGC CTT TTG GTA ATG CTG TTT-3′,
and reverse primer, 5′-GGC TTC ATA TAG TAC AGC
CTC CA-3′. Lastly, detection of the truncated isoformTable 2 Characteristics of control tissue samples
Sample ID# CASE # Age (years) Gender PMI (hours) Prim
C1 AN12552 56 Male 23.61 Trau
C2 AN17344 46 Male 25.9 Unk
C3 AN14771 30 Male 23 Car
C4 UMB818 27 Male 10 Mu
C5 AN17425 16 Male 26.16 Unk
C6 AN15240 36 Female 18.08 Unk
C7 AN19760 28 Male 23.25 Unk
C8 AN12240 51 Male 4.75 MI
C9 AN10606 56 Male 23 My
C10 UMB1706 8 Female 20 Reje
C11 UMB1860 8 Male 5 Car
C12 UMB1407 9 Female 20 Ast
C13 UMB1649 20 Male 22 Mu
Mean 28.5 18.8
SEM (+/−) 4.8 1.8
N/A = Information Not Available; PMI = Post Mortem Interval.TrkB-Shc was performed using forward primer, 5′-GGC
CCA GAT GCT GTC ATT AT-3′, and reverse primer,
5′-AGG CAT GGA TTT AGC CTC CT-3′. Copy num-
bers using absolute quantification and PCR efficiencies
were calculated with MXPro Mx3000P Software (Strata-
gene). Only experiments in which the real-time PCR ef-
ficiency was between 90%-100% and standard curves
yielded a R2 > 0.990 were used for analysis.ary cause of death Secondary cause of death
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Rat tissues were homogenized in RIPA buffer (Thermo
Scientific, Rockford, IL, USA) with protease (complete,
Mini, EDTA-free) and phophatase (PhosSTOP) inhibitor
cocktail tablets (Roche, Indianapolis, IN, USA). A similar
homogenization buffer [35] was used for human sam-
ples. Homogenates were sonicated, incubated on ice for
15–30 min and then centrifuged at 13000 × g for 10–
20 min at 4°C to precipitate insoluble debris. The super-
natants were collected and protein concentrations were
determined using the BCA protein assay kit (Thermo
Scientific, Rockford, IL, USA) or the DC™ protein assay
(Bio-Rad Laboratories, Mississauga, Ontario, Canada) as
described by the manufacturer. Rat tissue lysates were
pooled in order to handle a large number of samples
that exceeded the lane capacity of a gel, while human
homogenates were not pooled. Sample protein concen-
trations were adjusted to 4 μg/μl (rat) or 1.5-3.5 μg/μl
(human) for Western blotting.Western blotting and densitometry
10 to 40 μg total protein (depending on the target) was
separated on 8%-12% sodium dodecyl sulfate (SDS)-
polyacrylamide gels or Mini-PROTEAN® Precast Gels
(Bio-Rad, Hercules, CA, USA) under reducing condi-
tions and transferred to polyvinylidene fluoride (PVDF)
membranes (Bio-Rad, Hercules, CA, USA). Membranes
were then blocked with a 1:1 solution of phosphate-
buffered saline (PBS) pH7.4 and Odyssey Blocking Buffer
(BB) (Cedarlane, Burlington, Ontario, Canada) or 5%
nonfat milk in Tris-buffered saline solution containing
0.1% Tween 20 (TBS-T) for 1 hour. After blocking, the
blots were probed overnight at 4°C with the following
primary antibodies: TrkB (Cell Signaling Technology,
Danvers, MA, USA, diluted 1:700), PI3K p85, Akt,
phospho-Akt, mTOR, phospho-mTOR (Ser2448), 4E-
BP1, phospho-4E-BP1, eIF4E, eIF4B, S6, phospho-S6,
GFAP, βIII-Tubulin (Cell Signaling Technology, diluted
1:1000), p70S6K (Santa Cruz Biotechnology, diluted
1:500), and PSD-95 (Millipore, diluted 1:1000). Mem-
branes were simultaneously probed with mouse monoclo-
nal anti-β-actin antibody (Sigma, diluted 1:5000 or Cell
Signaling Technology, diluted 1:1000) as a loading control.
After washing with TBS-T, rat blots were incubated
with the secondary antibody horseradish peroxidase
(HRP)-conjugated goat anti-rabbit (Bio-Rad, Hercules,
CA, USA) for 1 hour at room temperature, washed with
TBS-T, exposed to Hyper film ECL (Amersham Pharmacia
Biotech, Carlsbad, CA, USA) and ultimately visualized
using the enhanced chemiluminescence (ECL) detection
system. Bands were detected and quantified using a
ChemiDOC MP gel imaging system (Bio-Rad, Hercules,
CA, USA).After washing with PBS containing 0.5% Tween-20
(PBS-T), human tissue blots were incubated with the
secondary antibodies IRDye 680-conjugated goat anti-
rabbit and IRDye 800CW-conjugated goat anti-mouse
(LI-COR Biosciences, Lincoln, NE, USA; diluted 1:8000)
for 1 hour at room temperature, washed with PBS-T
and scanned using an Odyssey® Infrared Imaging System
(LI-COR Biosciences). Band intensities were quantified
by densitometry with local background subtraction
using LI-COR® Odyssey Software, version 2.0.Statistical analysis
Each Western blot for human tissue contained a stand-
ard curve consisting of different amounts of protein
per lane (from 1 to 80 μg) from a single normal human
cortex sample to allow normalization between blots
and to ensure that the sample loading amount was in
the linear range of detection for all targets tested.
For both RT-PCR and Western blot experiments, each
human or rat sample was expressed as a ratio to its cor-
responding β-actin value.
Differences in the target mRNA or protein levels be-
tween autism, VPA and respective control samples were
calculated by 2-tailed Student’s t-test with statistical sig-
nificance set at p < 0.05.Results
Decreased PI3K p85, Akt, mTOR, phospho-mTOR, p70S6K
and eIF4B protein expression in idiopathic autism
Akt/mTOR pathway protein expression levels were ex-
amined in the fusiform gyrus of subjects with idiopathic
autism versus control subjects. Fusiform gyrus is an area
of the brain implicated in face discrimination and per-
ception difficulties of autistic subjects [29,32]. Western
blotting revealed a statistically significant decrease in
PI3K p85 and Akt (*p = 0.03, Figure 1A,B; *p = 0.03,
Figure 1C,D; 2-tailed t tests) protein in the fusiform
gyrus of autistic subjects relative to controls.
Total and phosphorylated mTOR were also decreased
in autism versus control brain (**p = 0.003, Figure 2A;
***p = 0.0003, Figure 2B; 2-tailed t tests).
We next examined the mTOR downstream effector
pathways p70S6K/eIF4B and 4E-BP1/eIF4E involved in
local dendritic protein translation. A statistically sig-
nificant decrease in p70S6K and eIF4B protein was
found (**p = 0.002, Figure 3A,B; *p = 0.02, Figure 3C,D;
2-tailed t tests) in the fusiform gyrus of autistic subjects
relative to controls. However, there were no significant
differences in protein expression levels of 4E-BP1 or
eIF4E (p = 0.6, Figure 3E,F; p = 0.4, Figure 3G,H; 2-
tailed t tests) in the fusiform gyrus of control vs. autism
subjects.
Figure 1 Quantification of (A) PI3K p85 and (C) Akt protein expression in fusiform gyrus of autism and control samples by Western
blotting. Each sample was normalized to its β-actin. *p = 0.03 for PI3K p85 and Akt, 2-tailed t tests. Bars indicate mean ± SE. Autism, n = 11;
control, n = 13. The mean from two independent Western blots per sample was used for statistical analysis. (B) and (D) Representative Western
blots of fusiform gyrus showing autism (A) and control (C) cases. 35 μg for PI3K p85 and 15 μg for Akt of total protein from each autism and
control sample were loaded.
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Because the Akt/mTOR pathway can influence protein
synthesis at spines, and de-regulated mTOR has been
associated with spine deficits in monogenic disorders
with high rates of autism [2,3,36], PSD-95 protein ex-
pression, a marker of excitatory synapses, was examined
in the fusiform gyrus of autism versus control subjects.
Western blotting revealed a significant decrease in PSD-
95 protein levels (*p = 0.02, Figure 4A,B; 2-tailed t test)
in individuals with idiopathic autism versus controls.Figure 2 Quantification by Western blotting and representative West
expression in autism versus control fusiform gyrus samples. Each sam
for phospho-mTOR, 2-tailed t tests. Bars indicate mean ± SE. Autism, n = 11
sample was used for statistical analysis. 35 μg for mTOR and 50 μg for pho
(C) sample were loaded.Imbalance in TrkB protein isoforms in idiopathic autism
The TrkB/Akt pathway is known to influence PSD-95
trafficking to spines [37]. Thus, differences in relative
TrkB protein isoform levels in fusiform gyrus between
autism and control groups were examined by Western
blotting. A significant reduction in full-length TrkB
(TrkB-FL)/truncated TrkB (TrkB-T1 + TrkB-Shc) isoform
ratio and increase in the ratio of truncated TrkB isoforms/
TrkB-FL (**p = 0.002, Figure 5A; **p = 0.009, Figure 5B; 2-
tailed t tests) were observed in the fusiform gyrus ofern blots of (A) total mTOR and (B) phospho-mTOR protein
ple was normalized to its β-actin. **p = 0.003 for mTOR, ***p = 0.0003
; control, n = 13. The mean from two independent Western blots per
spho-mTOR of total protein from each autism (A) and control
Figure 3 Quantification of (A) p70S6K, (C) eIF4B, (E) 4E-BP1 and (G) eIF4E protein expression in fusiform gyrus of autism and control
samples by Western blotting. Each sample was normalized to its β-actin. **p = 0.002 for p70S6K, *p = 0.02 for eIF4B, p = 0.6 for 4E-BP1 and p = 0.4 for
eIF4E, 2-tailed t tests. Bars indicate mean ± SE. Autism, n = 11; control, n = 13. The mean from two independent Western blots per sample was used for
statistical analysis. (B), (D), (F) and (H) Representative Western blots of fusiform gyrus showing autism (A) and control (C) cases. 35 μg for p70S6K, eIF4B
and 4E-BP1 and 20 μg for eIF4E of total protein from each autism and control sample were loaded.
Figure 4 Quantification of (A) PSD-95 protein expression in fusiform gyrus of autism and control samples by Western blotting. Each
sample was normalized to its β-actin. *p = 0.02, 2-tailed t test. Bars indicate mean ± SE. Autism, n = 11; control, n = 13. The mean from three
independent Western blots per sample was used for statistical analysis. (B) Representative Western blots of fusiform gyrus showing autism
(A) and control (C) cases. 20 μg of total protein from each autism and control sample were loaded.
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Figure 5 Quantification of (A) full-length (FL)/truncated and (B) truncated/full-length (FL) TrkB isoform protein ratios in fusiform gyrus of
autism and control samples. **p = 0.002 and **p = 0.009, respectively, 2-tailed t tests. Bars indicate mean ± SE. Autism, n = 11; control, n = 13.
(C) Quantification of full-length (FL) TrkB and (E) truncated TrkB isoform protein expression in fusiform gyrus of autism and control samples by Western
blotting. Each sample was normalized to its β-actin. **p = 0.003 for TrkB-FL and p = 0.09 for truncated TrkB isoforms, 2-tailed t tests. Bars indicate mean ±
SE. Autism, n = 11; control, n = 13. The mean from two independent Western blots per sample was used for statistical analysis. (D) and (F) Representative
Western blots of fusiform gyrus showing autism (A) and control (C) cases. Lanes 2 to 5: standard curve consisting of different amounts of total protein
from a single normal human cortex sample. Lanes 6 to 13: 35 μg of total protein from each autism and control sample.
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may be due to significantly decreased TrkB-FL (**p =
0.003, Figure 5C,D; 2-tailed t test) as well as a trend
towards increased truncated TrkB (p = 0.09, Figure 5E,F;
2-tailed t test). TrkB-FL and truncated TrkB are differen-
tially expressed in different cell types: TrkB-FL is neuronal
whereas truncated TrkB isoforms are widely expressed in
glia. Therefore, we measured protein levels of GFAP (glial)
and βIII-Tubulin (neuronal) markers. There were no signifi-
cant differences in GFAP or βIII-Tubulin protein expres-
sion in the fusiform gyrus (p = 0.4, Figure 6A,B; p = 0.5,
Figure 6C,D; 2-tailed t tests) between control and autism
subjects, which precludes differential cell loss as a mechan-
ism for TrkB isoform alterations. There were also no differ-
ences between groups in β-actin levels (p = 0.7, 2-tailed t
test, data not shown), which were used to normalize sam-
ples on the Western blots.No significant differences in TrkB isoform mRNA
levels were found in the fusiform gyrus between control
and autism subjects (TrkB-FL: p = 0.1; TrkB-T1: p = 0.3;
TrkB-Shc: p = 0.7; 2-tailed t tests; data not shown).
Decreased mTOR signaling in VPA-exposed rats
In this study, we specifically chose to examine idiopathic
autism. As epigenetics are thought to play a key role in
causing idiopathic autism, we also examined the brains
of rats exposed to the HDAC inhibitor VPA in utero.
We measured Akt, mTOR, S6K, and 4E-BP1 total and
phosphorylated protein levels in VPA- versus saline-
exposed rat lateral temporal neocortices.
Western blotting revealed a statistically significant de-
crease in both total and phosphorylated Akt (**p = 0.002,
Figure 7A; **p = 0.004, Figure 8A; 2-tailed t tests), mTOR
(***p < 0.0001, Figure 7B; ***p < 0.0001, Figure 8B; 2-tailed
Figure 6 Quantification of (A) Beta-III Tubulin and (C) GFAP protein expression in fusiform gyrus of autism and control samples by
Western blotting. Each sample was normalized to its β-actin. As reported by other studies [38,39], four bands ranging from 38 kDa to 50 kDa
were detected for GFAP in all samples and quantified together. p = 0.5 for βIII-tubulin, p = 0.4 for GFAP, 2-tailed t test. Bars indicate mean ± SE.
Autism, n = 11; control, n = 13. The mean from two independent Western blots per sample was used for statistical analysis. (B) and (D) Representative
Western blots of fusiform gyrus showing autism (A) and control (C) cases. 20 μg for Beta-III Tubulin and 5 μg for GFAP of total protein from each autism
and control sample were loaded.
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0.0001, Figure 8D; 2-tailed t tests) in VPA-exposed rats
compared to saline-exposed controls. However, only phos-
phorylated (***p < 0.0001, Figure 8C; 2-tailed t test) but
not total (p = 0.6, Figure 7C; 2-tailed t test) S6 protein ex-
pression was significantly reduced in VPA- versus saline-
exposed rats.
Discussion
Studies of single-gene disorders with a high prevalence
of autism such as Rett syndrome (mutations in MeCP2),
fragile X syndrome (mutations in FMR1), tuberous scler-
osis (mutations in TSC1/TSC2), neurofibromatosis (mu-
tations in NF1), and macrocephaly (mutations in PTEN),
point to the Akt/mTOR pathway as a good candidate for
involvement in autism pathogenesis [2-5,36,40,41]. In
the present study, we demonstrate that, in contrast to
fragile X syndrome, tuberous sclerosis, neurofibroma-
tosis 1 and macrocephaly which exhibit increased mTOR
pathway components [2,3,5], the mTOR pathway is de-
creased in idiopathic autism. Our findings are consistent
with previous reports of reduced mTOR pathway in Rett
syndrome [36] and decreased Akt total protein and phos-
phorylation in frontal cerebral cortex from autistic pa-
tients [42]. This supports the idea that mTOR pathway
deviations in either direction can adversely affect estab-
lishment, maintenance and function of neural networksand thus ultimately cause autism’s cognitive and behav-
ioural deficits [43].
As several of our subjects with autism exhibited sei-
zures (n = 4), while others did not (n = 6), results from
these two groups of patients were compared. No differ-
ences in levels of any of the proteins studied (PI3K p85,
Akt, total and phosphorylated mTOR, TrkB isoforms,
p70S6K, eIF4B or PSD-95) were found between autism
cases with seizure disorder and those without (p > 0.05,
2-tailed t tests). This is consistent with our previous
findings for BDNF [28]. BDNF mRNA is highly sensitive
to seizures, and yet in that study, none of our autistic
subjects with seizures (the same ones as used in this
study) exhibited higher BDNF mRNA levels than those
without.
mTOR regulates protein synthesis at synapses via two
distinct downstream pathways which are responsible for
promoting translation of different pools of mRNAs
[44,45]. The p70S6K and eukaryotic initiation factor 4B
(eIF4B) cascade regulates translation of mRNAs encoding
translational machinery components such as elongation
and initiation factors and ribosomal proteins, while the
eukaryotic initiation factor 4E-binding protein 1 (4E-BP1)
and eukaryotic initiation factor 4E (eIF4E) pathway control
translation of 5′ capped mRNAs coding for structural and
functional synaptic proteins [46,47]. Single nucleotide in-
sertions in the promoter of the mTOR effector eIF4E are
Figure 7 Quantification by Western blotting and representative Western blots of total (A) Akt, (B) mTOR, (C) S6 and (D) 4E-BP1 protein
expression in VPA- versus saline (SAL)-exposed rat lateral temporal neocortices. Each sample was normalized to its β-actin, and VPA-exposed
values were expressed relative to SAL-exposed. All p-values were calculated by 2-tailed t test. Akt: **p = 0.002, SAL, n = 5; VPA, n = 5; mTOR: ***p <
0.0001, SAL, n = 8; VPA, n = 8; S6: p = 0.5, SAL, n = 8; VPA, n = 8; 4E-BP1: ***p < 0.0001, SAL, n = 6; VPA, n = 6. Bars indicate mean ± SE. The mean from
three independent Western blots per sample was used for statistical analysis.
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families [5], and linkage of autism to the eIF4E region on
chromosome 4q shown in genome-wide association stud-
ies [48] suggest that this pathway may be preferentially
affected in genetic causes of autism. Conversely, in our
study, autistic subjects had significantly decreased p70S6K
and eIF4B, while there were no changes in 4E-BP1 or
eIF4E in these patients, pointing to specific deficits in
mTOR-dependent translation via the p70S6K/S6 pathway
in idiopathic autism.
Overall, nine of our eleven autism subjects, regardless
of whether they had concurrent seizure disorder, exhib-
ited decreases throughout the mTOR pathway (Table 3).
The direction of change is uniform for each subject, sug-
gesting coordinated or feedback regulation of the path-
way. Our findings demonstrate that disruptions in
mTOR and its signaling cascade components are wide-
spread in the autism population and not limited to gen-
etic forms of autism.
In support of this evidence, our animal data point to
epigenetic mechanisms as a likely underlying cause of
these disruptions. We are the first to report that mater-
nal exposure to the anticonvulsant VPA, an HDACinhibitor, results in decreased mTOR signaling in lateral
temporal neocortices of rats. Significantly down-regulated
protein levels of mTOR as well as its upstream/down-
stream effectors were associated with a significant reduc-
tion in the overall amount of social play behaviors and an
attenuated response to playful attacks in VPA- versus
saline-exposed control rats [34,49], corroborating the hy-
pothesis that reduced mTOR pathway signaling contrib-
utes to autistic behaviors.
In contrast to idiopathic autism which exhibits only S6
pathway deficits, both mTOR downstream effector cas-
cades appear to be affected in VPA-exposed rats, as defi-
cits were found in phosphorylated S6 and 4E-BP1. It is
possible that these differences in down-regulated mTOR
effectors between rat and human may specifically under-
lie autistic-like behavior caused by VPA treatment.
A consequence of dysfunctional mTOR signaling is
deficits in spine protein translation and changes in spine
morphology, density and dynamics [3,36]. Abnormal
spine density and morphology have been reported in
cortical neurons from autistic subjects [7,50]. Interestingly,
we observed that decreased mTOR was associated with a
significant reduction of PSD-95, a key postsynaptic density
Figure 8 Quantification by Western blotting and representative Western blots of phosphorylated (A) Akt, (B) mTOR, (C) S6 and
(D) 4E-BP1 protein expression in VPA- versus saline (SAL)-exposed rat lateral temporal neocortices. Each sample was normalized to its
β-actin, and VPA-exposed values were expressed relative to SAL-exposed. All p-values were calculated by 2-tailed t test. Phospho-Akt: **p = 0.004, SAL,
n = 4; VPA, n = 4; phospho-mTOR: ***p < 0.0001, SAL, n = 8; VPA, n = 8; phospho-S6: ***p < 0.0001, SAL, n = 8; VPA, n = 8; phospho-4E-BP1: ***p <
0.0001, SAL, n = 6; VPA, n = 6. Bars indicate mean ± SE. The mean from three independent Western blots per sample was used for statistical analysis.
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trols. There are several mechanisms at work which might
impact levels of PSD-95. The high-affinity brain-derived
neurotrophic factor (BDNF) receptor TrkB regulates traf-
ficking of PSD-95 at synapses via PI3K-Akt [37]. Interest-
ingly, TrkB involvement in autism pathogenesis is
substantiated by the finding of an association between
trkB (nTrk2) gene variants and autism [51]. Consistently,
we discovered significantly decreased protein levels of full-
length TrkB (TrkB-FL), a trend towards increased trun-
cated TrkB isoform protein levels and significantly altered
TrkB isoform ratios in autism versus control subjects, sup-
porting a TrkB isoform imbalance in autism similar to
other neuropsychiatric disorders such as schizophrenia
[52,53]. By interfering with PSD-95 transport at synapses
via PI3K/Akt, decreased TrkB-FL may negatively affect
spines and thus might impair neural networks which sub-
serve higher cognitive functions and behavior. Reduced
TrkB might also contribute to the Akt/mTOR pathway
down-regulation seen in idiopathic autism, since TrkB-FL
contains the intracellular catalytic tyrosine kinase domain
needed to activate TrkB-mediated signaling cascades, in-
cluding the Akt/mTOR pathway, upon BDNF binding
[54]. Additionally, truncated TrkB isoforms, which lackthe tyrosine kinase activity and thus can only bind and se-
quester BDNF but cannot activate downstream signaling
cascades [55,56], could act as negative regulators by
trapping BDNF or by forming heterodimers with TrkB-FL
receptors [57-59], and further down-regulate the Akt/
mTOR pathway.
TrkB-FL is expressed almost exclusively in pyramidal
neurons and interneurons [60-62], whereas truncated iso-
forms are found in both neurons and glia [63,64]. How-
ever, no differences in either GFAP or βIII-Tubulin levels
between autism and control subjects were detected, dem-
onstrating that these TrkB isoform imbalances are not due
to a shift in the proportion of neurons versus glia. Also, as
no alterations were observed in TrkB isoform mRNA, it is
likely that translational and/or post-translational mecha-
nisms may contribute to the abnormal ratio of TrkB iso-
forms seen in the autistic brain.
In summary, our study is the first to demonstrate
major decreases in protein expression and phosphoryl-
ation for mTOR and components of its downstream sig-
naling pathways in subjects with idiopathic autism.
These data demonstrate that deficits in this pathway are
widespread in idiopathic autism and that up- or down-
regulation of this pathway can have equally disruptive
Table 3 Distribution of analyzed protein targets from autism subjects relative to controls























TrkB-FL −2.0 SD −1.5 SD −2.0 SD −1.5 SD 0.5 SD −0.5 SD 0.5 SD −2.0 SD −2.0 SD −1.5 SD −1.5 SD
PI3K p85 −2.0 SD −1.5 SD −2.0 SD −2.0 SD 0.5 SD −0.5 SD 0.5 SD −2.0 SD −2.0 SD 1.5 SD −1.5 SD
Akt −2.0 SD −0.5 SD −1.5 SD −2.0 SD 1.5 SD −0.5 SD 0.5 SD −1.5 SD −1.5 SD −0.5 SD −1.5 SD
mTOR −2.0 SD −2.0 SD −2.0 SD −2.0 SD 1.5 SD −0.5 SD 0.5 SD −2.0 SD −2.0 SD −1.5 SD −2.0 SD
Phospho-mTOR −1.5 SD −2.0 SD −2.0 SD −2.0 SD 0.5 SD −0.5 SD −0.5 SD −2.0 SD −2.0 SD −2.0 SD −2.0 SD
p70 S6 Kinase −2.0 SD −1.5 SD −1.5 SD −2.0 SD 0.5 SD −0.5 SD −0.5 SD −1.5 SD −2.0 SD −1.5 SD −1.5 SD
eIF4B −2.0 SD −2.0 SD −2.0 SD −1.5 SD 1.5 SD 2.0 SD −0.5 SD −1.5 SD −2.0 SD −2.0 SD −2.0 SD
PSD-95 −1.5 SD −1.5 SD −1.5 SD −1.5 SD 0.5 SD 0.5 SD 0.5 SD −1.5 SD −1.5 SD −1.5 SD −1.5 SD
SD = Standard deviation. The mean of each target for the control group was used as a reference to calculate the corresponding standard deviation values for each target. Bold-Italics = 0.5-2.0 standard deviations less
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ported by similar alterations in VPA-exposed rats, point-
ing to epigenetic mechanisms as the underlying molecular
substrate of these disruptions. Despite minor differences
in down-regulated mTOR cascade effectors, our human
and animal data identify dysfunctional mTOR as a com-
mon molecular mechanism underlying autistic traits and
suggest that a disruption of this pathway in either direc-
tion can have adverse consequences for dendritic spines,
as supported by decreased PSD-95, and thus ultimately for
synaptic development and function. In conclusion, our
present findings highlight that decreased mTOR is likely
to adversely affect spines and ultimately cortical circuits
implicated in higher cognitive functions and behavior
causing autistic phenotypes.
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